Nociceptive vs Neuropathic vs Nociplastic Pain

Table of Contents

  1. Why the Label You Get Changes Your Treatment
  2. The IASP 2017 Taxonomy — A Third Category Appears
  3. Nociceptive Pain: The Alarm System Working Correctly
  4. Neuropathic Pain: A Damaged Wire
  5. Nociplastic Pain: The Volume Knob Stuck on High
  6. Screening Tools — DN4, painDETECT, and the Nociplastic Criteria
  7. Quantitative Sensory Testing
  8. Why Mixed Presentations Are the Rule, Not the Exception
  9. The Treatment Map — What Actually Works for Each Type
  10. What to Ask Your Clinician
  11. Key Research Papers
  12. Research Papers
  13. Connections

Why the Label You Get Changes Your Treatment

If you live with chronic pain, the single most useful sentence your clinician can say is not "your pain is real" — you already know that. It is "your pain looks mostly nociceptive" or "neuropathic" or "nociplastic." Those three words are not jargon. They describe three different biological mechanisms, and each one responds to a completely different set of treatments. Getting the mechanism right can be the difference between years of mediocre relief and a treatment plan that actually moves your numbers.

The problem: most people with chronic pain never hear these words. They get diagnosed with an anatomical label (e.g., "low back pain," "fibromyalgia," "post-herpetic neuralgia") and then get handed a medication menu that was written for the average chronic pain patient — which often means NSAIDs first, opioids if things escalate, and a lot of shrugging. That is not how modern pain medicine is supposed to work. The International Association for the Study of Pain (IASP) formalized a three-mechanism framework in 2017, and this article walks you through it in plain language.

The IASP 2017 Taxonomy — A Third Category Appears

For most of the 20th century, pain medicine worked with two mechanisms:

But clinicians kept seeing patients whose pain did not fit either bucket. Fibromyalgia patients had no detectable tissue damage and no identifiable nerve lesion — yet their pain was objectively severe and measurably disabling. Irritable bowel syndrome patients had normal colonoscopies but excruciating cramps. Chronic whiplash patients had normal imaging but hypersensitive necks. Calling these cases "psychogenic" or "functional" was a clinical and ethical failure — the pain was real, it was just being generated by a different mechanism.

In 2017 the IASP formally adopted a third mechanistic descriptor: nociplastic pain. The term combines "nociception" (pain signaling) with "plastic" (as in neuroplasticity — the nervous system's ability to change its own wiring). Nociplastic pain arises from altered nociception in the central nervous system, despite no clear evidence of actual or threatened tissue damage and no evidence of disease or lesion of the somatosensory system. The pain is not imagined; the signal-processing has been turned up.

Think of your nervous system as an audio mixing board. Nociceptive pain is a loud sound from an instrument. Neuropathic pain is a damaged microphone crackling. Nociplastic pain is the master volume knob stuck on maximum — every normal sound becomes painful even when nothing unusual is happening on stage.

Nociceptive Pain: The Alarm System Working Correctly

What it is. Nociceptive pain is what pain is supposed to do. Specialized sensory neurons called nociceptors, embedded in skin, muscle, bone, joints, and viscera, detect mechanical, thermal, or chemical threats and send a signal up the spinal cord to the brain. You pull your hand off the stove. You limp on the sprained ankle. The system works.

What it feels like. Patients describe nociceptive pain with concrete, localized words:

Classic examples. Osteoarthritis of the knee, a freshly sprained ankle, a kidney stone, post-surgical incisional pain, a toothache, bone metastasis, menstrual cramps. If you can point to the sore spot with one finger and reproduce the pain by pressing on it, you are usually dealing with nociceptive pain.

What works. Nociceptive pain is the one kind that responds reliably to the drugs most people already know:

Gabapentin, pregabalin, and duloxetine usually do not help pure nociceptive pain. Prescribing them for an osteoarthritic knee is a common mistake that delays effective care.

Neuropathic Pain: A Damaged Wire

What it is. Neuropathic pain arises from damage or disease of the somatosensory system itself — the peripheral nerves, dorsal roots, spinal cord, or brain regions that carry sensory information. The wire that normally transmits touch, temperature, and position sense has been injured, and it is now firing spontaneously or amplifying normal input into pain.

What it feels like. The vocabulary is strikingly different from nociceptive pain. Ask a patient with diabetic neuropathy or postherpetic neuralgia and you will hear:

Classic examples. Diabetic peripheral neuropathy, postherpetic neuralgia (shingles), sciatica from a compressed lumbar nerve root, trigeminal neuralgia, chemotherapy-induced peripheral neuropathy, central post-stroke pain, spinal-cord-injury pain, and multiple sclerosis. See peripheral neuropathy for detail on peripheral forms.

Screening tools. Two validated questionnaires help identify neuropathic pain quickly:

Neither questionnaire diagnoses on its own — they flag the pattern so your clinician can order confirmatory testing (nerve conduction studies, skin biopsy for small-fiber neuropathy, MRI of the affected region).

What works. Pure nociceptive drugs usually underperform here. First-line evidence-based treatments for neuropathic pain include:

NSAIDs and acetaminophen rarely do much for neuropathic pain. Opioids have modest efficacy but poor long-term risk-benefit.

Nociplastic Pain: The Volume Knob Stuck on High

What it is. Nociplastic pain arises from altered central nociceptive processing — the spinal cord and brain amplify, maintain, and generate pain signals in the absence of ongoing tissue or nerve damage. The peripheral hardware is essentially fine. The signal processing has changed.

What it feels like. Nociplastic pain has a distinctive clinical signature:

Classic examples. Fibromyalgia is the prototype. Other conditions that are predominantly or frequently nociplastic include irritable bowel syndrome, chronic pelvic pain, vulvodynia, chronic tension headache, temporomandibular disorders, interstitial cystitis, chronic low back pain without a clear structural driver, and a substantial fraction of long-standing chronic fatigue syndrome patients. See fibromyalgia, central sensitization explained, and chronic fatigue syndrome.

Diagnostic criteria. In 2021 an IASP working group (Kosek et al., Pain) proposed provisional clinical criteria for identifying nociplastic pain in the musculoskeletal system. A patient should have pain for at least three months, a regional (not strictly dermatomal or single-joint) distribution, and no convincing evidence that nociceptive or neuropathic mechanisms alone explain the pain. Supporting features include hypersensitivity to pressure, temperature, or sound; non-restorative sleep; fatigue; and cognitive problems. The criteria are explicitly a clinical framework, not a blood test.

What works. This is where the treatment map diverges most sharply from the other two categories:

What tends not to work for pure nociplastic pain: NSAIDs, acetaminophen, opioids (often worsen things long-term via opioid-induced hyperalgesia), joint injections, and surgery targeted at incidental imaging findings. Many fibromyalgia patients have spent a decade cycling through these before anyone names the mechanism.

Screening Tools — DN4, painDETECT, and the Nociplastic Criteria

You can bring these to an appointment and ask your clinician to walk through them with you. Most take five minutes.

Quantitative Sensory Testing

Quantitative sensory testing (QST) is a standardized battery of bedside and laboratory measurements that probe how your nervous system responds to calibrated stimuli — warm, cold, mechanical pressure, pinprick, vibration. The best-known protocol is the German Research Network on Neuropathic Pain (DFNS) standard, which generates a profile of sensory gains (hypersensitivity) and losses (hyposensitivity).

QST is not routine clinical care yet, but it can help in three ways:

Access is limited to academic pain centers. If you are in a complex diagnostic situation, asking for referral to a pain-medicine program that runs QST is reasonable.

Why Mixed Presentations Are the Rule, Not the Exception

The three-mechanism taxonomy is a useful map, but real patients rarely live in only one country on the map. Mechanistic overlap is the norm for three reasons:

1. Persistent nociceptive input can drive central sensitization. If you have osteoarthritis of the knee and it hurts every day for years, your spinal cord and brain slowly rewire to amplify the signal. At some point the knee itself is no longer the whole story — the central nervous system has become an independent generator. This is why a meaningful fraction of patients with "end-stage" knee OA still hurt after a perfect knee replacement. The hardware was fixed; the software was not.

2. Nerve injury can trigger central sensitization. Postherpetic neuralgia, post-surgical nerve injury, and complex regional pain syndrome all start as peripheral nerve events and progress to mixed neuropathic-plus-nociplastic states. See complex regional pain syndrome.

3. Nociplastic pain amplifies everything else. A fibromyalgia patient who develops a rotator-cuff tear will experience far more pain than a matched patient without fibromyalgia. The nociplastic background amplifies the nociceptive foreground.

Clinically, this means you should not be surprised if your doctor says your pain is "mostly nociplastic with a nociceptive component" or "neuropathic with central sensitization." The practical question becomes which mechanism is driving the most disability right now, because that is the one to target first.

The Treatment Map — What Actually Works for Each Type

A simplified cheat sheet. Use it as a starting point with your clinician, not a replacement for individualized care.

Note the overlap: duloxetine and pregabalin appear in both neuropathic and nociplastic columns. That is not an accident. Both drugs modulate central signaling, which is why they help two seemingly different mechanisms that share a downstream amplification step.

What to Ask Your Clinician

You will get faster, better care if you can frame your visit around the mechanism question rather than the symptom list alone. Concrete asks:

A clinician who cannot or will not engage with these questions is not necessarily a bad clinician — many primary care providers simply have not been trained in the 2017 taxonomy. In that case, ask for referral to a pain medicine specialist, a rheumatologist, or a neurologist (depending on the suspected mechanism). You do not have to settle for "let's try another NSAID."

The bottom line: chronic pain is not one disease. It is at least three different signal-processing problems that happen to hurt. Matching the treatment to the mechanism is the most useful thing you and your clinical team can do together.

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on pain mechanisms, screening, and treatment:

  1. Nociplastic pain mechanisms
  2. IASP taxonomy of chronic pain
  3. Neuropathic pain screening with DN4 and painDETECT
  4. Central sensitization in fibromyalgia
  5. Quantitative sensory testing in chronic pain
  6. Duloxetine for fibromyalgia and nociplastic pain
  7. Low-dose naltrexone in fibromyalgia
  8. Mixed pain mechanisms and treatment strategy

Connections

Back to Table of Contents